AVITA Medical & Gates Center unite to explore spray-on skin treatment
Category: #health  By Pankaj Singh  Date: 2019-11-25
  • share
  • Twitter
  • Facebook
  • LinkedIn

AVITA Medical & Gates Center unite to explore spray-on skin treatment

AVITA Medical and Gates Center for Regenerative Medicine have reportedly inked a Sponsored Research Agreement or SRA to develop treatments for genetic skin conditions. The firms will conduct preclinical trials to develop spray-on skin treatments using genetically modified skin cells to treat epidermolysis bullosa (EB) patients as well as other genetic skin disorders.

This collaboration will bring together AVITA Medical’s patented Spray-On Skin™ Cells technology and Gates Center’s unique, patent-pending gene editing and combined reprogramming technology to improve cell function. As per the SRA terms, AVITA Medical will retain the option to obtain an exclusive license for further progression and commercialization of technologies that emerge during the collaboration.

The Gates Center team is backed by numerous prominent medical organizations. The collective efforts of the New York-based EB Research Partnership, London-based Cure EB Charity, L.A-based EB Medical Research Foundation, as well as government grants will help advance and render this technology to clinics to enhance patient lives.

Dr. Mike Perry, CEO of AVITA Medical & adjunct professor at the Gates Center has apparently stated that the Gates center has made significant strides in the treatment of genetic skin conditions, particularly epidermolysis bullosa.  He further expressed his anticipation towards working together with the Gates Center team to further advance AVITA’s Spray-On Skin™ Cells technology. The collaboration is a significant breakthrough for AVITA in their mission to harness regenerative medicine to treat unmet dermatological needs, including genetic skin disorders.

Gates Center for Regenerative Medicine Director, Dr. Dennis Roop also spoke about the partnership, expressing his eagerness to partner with AVITA Medical in an effort to further their epidermolysis bullosa program. He stated that this alliance will help discover and advance new approaches towards genetic skin conditions, by treating patients through the use of gene-edited skin cells.

Dr. Ganna Bilousova, assistant professor of dermatology & the research program’s co-principal investigator has also expressed his belief that the combination of AVITA’s Spray-On Skin™ Cells technology and Gates Center’s genetically modified skin cells will help advance their EB treatment program. Dr. Bilousova claims that this collaboration will help reduce treatment time, lower manufacturing complexity and improve treatment results, in addition to lowering costs.

Source Credit: https://www.avitamedical.com/uploads/pdf/AVH-Press-Release-EB-CU-Denver-Partnership-25NOV2019-FINAL.pdf



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

Aoyuan Healthy to acquire 55% equity interest in Liantianmei
Aoyuan Healthy to acquire 55% equity interest in Liantianmei
By Pankaj Singh

Aoyuan Healthy Life Group Company Ltd., a renowned commercial property operation service and property management service provider based in China, has reportedly announced that Guangdong Xinyuerong Industrial Investment...

Anova Enterprises expands AnovaOS™ to boost clinical development
Anova Enterprises expands AnovaOS™ to boost clinical development
By Pankaj Singh

The U.S-based Anova Enterprises, Inc. (Anova) has reportedly expanded the AnovaOS™ technology platform in order to boost the development of promising novel treatments. The platform brings pharmaceutical companies...

Serum Institute to Resume Oxford COVID-19 Vaccine’s Trail in India
Serum Institute to Resume Oxford COVID-19 Vaccine’s Trail in India
By Pankaj Singh

India’s Drugs Controller General (DCGI) has approved Pune-based Serum Institute of India (SII) to restart the clinical trial of the Oxford/AstraZeneca COVID-19 vaccine in India.